7 Health Ventures

The firm concentrates on seed and Series A stages, where its domain expertise and operator networks can materially influence early company formation. This conviction-stage approach allows for meaningful engagement with founding teams as they navigate healthcare's regulatory and reimbursement complexity. Later-stage and growth-equity opportunities fall outside the firm's disclosed mandate.

The firm's mandate excludes biotech, pharmaceuticals, medical devices, diagnostics hardware, and general SaaS platforms with no healthcare-specific workflow integration. This negative screen distinguishes it from broad-spectrum healthtech funds that mix therapeutics, devices, and software under one strategy.

Sourcing relies on domain-specific operator networks within healthcare delivery organizations, payer systems, and health system innovation groups. The firm's singular industry focus creates referral density from clinicians-turned-founders and health system executives. No proprietary data platform or public deal-flow disclosure mechanism has been identified in available records.

Public records suggest the firm both leads and co-leads early-stage rounds, consistent with the profile of a conviction-driven sector specialist. Co-investment partners are not systematically disclosed. The firm does not appear to operate as a passive LP in other venture funds or as a fund-of-funds.

Available public information points to a traditional venture capital firm structure raising third-party capital rather than a single-family office vehicle. The absence of disclosed wealth-origin narratives and the sector-specialist positioning align with institutional, multi-LP fund architecture.